SG10201805670QA - Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders - Google Patents

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Info

Publication number
SG10201805670QA
SG10201805670QA SG10201805670QA SG10201805670QA SG10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA SG 10201805670Q A SG10201805670Q A SG 10201805670QA
Authority
SG
Singapore
Prior art keywords
disorders
senescence
methods
diseases
senescent cells
Prior art date
Application number
SG10201805670QA
Other languages
English (en)
Inventor
Remi-Martin Laberge
Judith Campisi
Albert Davalos
Marco Demaria
Nathaniel David
Alain Vasserot
Darren Baker
Bennett Childs
James Kirkland
Tamar Tchkonia
Deursen Jan Van
Yi Zhu
Jennifer Elisseeff
Chaekyu Kim
Okhee Jeon
Original Assignee
Buck Inst Res Aging
Unity Biotechnology Inc
Mayo Found Medical Education & Res
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Inst Res Aging, Unity Biotechnology Inc, Mayo Found Medical Education & Res, Univ Johns Hopkins filed Critical Buck Inst Res Aging
Publication of SG10201805670QA publication Critical patent/SG10201805670QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
SG10201805670QA 2014-01-28 2015-01-28 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders SG10201805670QA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461932711P 2014-01-28 2014-01-28
US201461932704P 2014-01-28 2014-01-28
US201461979911P 2014-04-15 2014-04-15
US201462002709P 2014-05-23 2014-05-23
US201462042708P 2014-08-27 2014-08-27
US201462044664P 2014-09-02 2014-09-02
US201462057820P 2014-09-30 2014-09-30
US201462057828P 2014-09-30 2014-09-30
US201462057825P 2014-09-30 2014-09-30
US201462061629P 2014-10-08 2014-10-08
US201462061627P 2014-10-08 2014-10-08

Publications (1)

Publication Number Publication Date
SG10201805670QA true SG10201805670QA (en) 2018-08-30

Family

ID=53757701

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805670QA SG10201805670QA (en) 2014-01-28 2015-01-28 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
SG11201606239UA SG11201606239UA (en) 2014-01-28 2015-01-28 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606239UA SG11201606239UA (en) 2014-01-28 2015-01-28 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Country Status (15)

Country Link
US (19) US9993472B2 (fr)
EP (2) EP3669881B1 (fr)
JP (5) JP6688224B2 (fr)
KR (1) KR102496146B1 (fr)
CN (3) CN110623956A (fr)
AU (3) AU2015211021B2 (fr)
BR (1) BR112016017564A8 (fr)
CA (2) CA3100140C (fr)
HK (1) HK1231392A1 (fr)
IL (3) IL286427B2 (fr)
MX (2) MX2016009753A (fr)
NZ (1) NZ723035A (fr)
RU (1) RU2716256C2 (fr)
SG (2) SG10201805670QA (fr)
WO (1) WO2015116740A1 (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
EP3511017A1 (fr) 2010-09-27 2019-07-17 Siwa Corporation Élimination sélective de cellules modifiées par l'âge pour le traitement de l'athérosclérose
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2015116740A1 (fr) 2014-01-28 2015-08-06 Buck Institute For Research On Aging Procédés et compositions permettant de tuer les cellules sénescentes et de traiter les maladies et les troubles associés à la sénescence
US20190269675A1 (en) * 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2015171723A1 (fr) * 2014-05-06 2015-11-12 Research Development Foundation Méthodes pour traiter la résistance à l'insuline et pour sensibiliser des patients à un traitement avec un agoniste du glp1
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
CA2961603C (fr) 2014-09-19 2021-07-13 Siwa Corporation Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
EP3253387A4 (fr) * 2015-02-06 2018-12-19 Unity Biotechnology, Inc. Composés et utilisations dans le traitement d' états associés à la sénescence
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2016135732A1 (fr) * 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Procédé favorisant la pousse des cheveux
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017002120A1 (fr) * 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Inhibiteurs sélectifs de cellules sénescentes et leurs utilisations
WO2017101851A1 (fr) * 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Dérivés acylsulfonamide pour le traitement de maladies et de troubles associés à la sénescence
EP3337829B1 (fr) 2016-02-19 2020-01-08 Siwa Corporation Procédé et composition pour traiter le cancer, détruire les cellules cancéreuses métastatiques et prévenir la métastase cancéreuse en utilisant des anticorps contre les produits terminaux de glycation avancée (age)
AU2017233886B2 (en) 2016-03-15 2022-10-20 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
AU2017254687B2 (en) * 2016-04-21 2021-09-30 Bioventures, Llc. Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US20190054097A1 (en) * 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
WO2017223107A1 (fr) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Thérapie enzymatique modifiant le génome pour des maladies modulées par des cellules sénescentes
EP3475306A1 (fr) 2016-06-23 2019-05-01 Siwa Corporation Vaccins pour l'utilisation dans le traitement de diverses maladies et troubles
JP7077335B2 (ja) 2016-12-13 2022-05-30 プリンストン ドラッグ ディスカバリー インコーポレイテッド プロテインキナーゼ阻害剤
WO2018129007A1 (fr) 2017-01-03 2018-07-12 Bioatla Llc Agents thérapeutiques protéiques pour le traitement de cellules sénescentes
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US20200041492A1 (en) 2017-03-09 2020-02-06 Rijksuniversiteit Groningen Biomarkers for cellular senescence
EP3609923A1 (fr) 2017-04-13 2020-02-19 Siwa Corporation Anticorps monoclonal humanisé de produit final de glycation avancée
TWI651087B (zh) * 2017-04-21 2019-02-21 長庚大學 類泛素化抑制劑於預防或治療骨質疏鬆症的用途
KR20240006702A (ko) * 2017-05-04 2024-01-15 시와 코퍼레이션 진단용 최종 당화 산물 항체
AU2018202878A1 (en) * 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3624821A4 (fr) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University Enzastaurine et agents augmentant l'activité du gène fhit (fragile histidine triad) pour le traitement de l'hypertension pulmonaire (pah)
GB201708456D0 (en) * 2017-05-26 2017-07-12 Medical Res Council Senolytic compounds
US20180344865A1 (en) * 2017-05-31 2018-12-06 Palo Alto Investors Methods of Increasing Fertility in a Female Subject
MX2019015095A (es) * 2017-06-16 2020-08-17 Unity Biotechnology Inc Metodo de sintesis para producir compuestos de cis-imidazolina enantiomericamente puros para uso farmaceutico.
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
WO2019033119A1 (fr) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. Traitement d'états ophtalmiques tels que la dégénérescence maculaire, le glaucome et la rétinopathie diabétique à l'aide d'agents pharmaceutiques qui éliminent les cellules sénescentes
JP7370599B2 (ja) * 2017-10-06 2023-10-30 バック・インスティテュート・フォー・リサーチ・オン・エイジング 老化細胞のためのバイオマーカー
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CA3043103C (fr) 2017-12-30 2021-02-09 Unity Biotechnology Inhibiteurs de proteasome fonde sur un peptide pour le traitement de troubles medies par des cellules senescentes et le traitement du cancer
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US20200360386A1 (en) * 2017-12-30 2020-11-19 Unity Biotechnology, Inc. Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions
WO2019144117A1 (fr) * 2018-01-22 2019-07-25 Bioventures, Llc Agents de dégradation de protéines bcl-2 pour le traitement du cancer
US20210109109A1 (en) * 2018-02-21 2021-04-15 Edifice Health, Inc. Method for measuring systemic chronic inflammaging
WO2019183282A1 (fr) * 2018-03-21 2019-09-26 Mayo Foundation For Medical Education And Research Agents sénolytiques pour le traitement de tauopathies
WO2019198091A1 (fr) 2018-04-12 2019-10-17 Yeda Research And Development Co. Ltd. Traitement à base de sang
CA3056878C (fr) 2018-04-30 2021-03-30 Unity Biotechnology Phospholidines qui sont des antagonistes de la famille bcl destinees a la gestion clinique des etats causes ou medies par les cellules senescentes et au traitement du cancer
JP7089062B2 (ja) 2018-04-30 2022-06-21 ユニティ バイオテクノロジー インコーポレイテッド 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン
US10738042B2 (en) 2018-04-30 2020-08-11 Unity Biotechnology, Inc. Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
TWI741286B (zh) 2018-04-30 2021-10-01 美商卡托斯醫療公司 治療癌症之方法
WO2019217973A1 (fr) 2018-05-11 2019-11-14 Rhode Island Hospital Compositions et méthodes pour traiter des troubles articulaires avec des inhibiteurs nucléosidiques de la transcriptase inverse
WO2019221755A1 (fr) 2018-05-18 2019-11-21 Bioventures, Llc Analogues de piperlongumine et leurs utilisations
EP3803409A1 (fr) * 2018-05-24 2021-04-14 Renibus Therapeutics, Inc. Procédés de traitement de patients présentant un risque de lésion rénale et d'insuffisance rénale
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2019246577A1 (fr) 2018-06-22 2019-12-26 Mayo Foundation For Medical Education And Research Procédés et matériaux pour améliorer la maturation de fistule artério-veineuse et maintenir une fonctionnalité de fistule artério-veineuse
US11026963B2 (en) 2018-07-11 2021-06-08 Rubedo Life Sciences, Inc. Senolytic compositions and uses thereof
CN112673259A (zh) * 2018-07-20 2021-04-16 豪夫迈·罗氏有限公司 基于igfbp-7的先兆子痫预测
CN109406764B (zh) * 2018-09-13 2022-02-01 中国辐射防护研究院 腹腔放疗后药物体内过程评价动物模型的建立与评价方法
WO2020061216A1 (fr) * 2018-09-18 2020-03-26 Signalchem Lifesciences Corporation Polythérapie pour traiter le cancer du sang
WO2020119614A1 (fr) * 2018-12-14 2020-06-18 Ascentage Pharma (Suzhou) Co., Ltd. Composé pour le traitement de l'arthrose
WO2020132053A1 (fr) * 2018-12-20 2020-06-25 Mayo Foundation For Medical Education And Research Méthodes et matériaux pour traiter des troubles neuropsychiatriques
FR3091864B1 (fr) 2019-01-20 2022-07-29 Waterdiam France Eau électrolysée, procédé d’obtention et utilisations d’une telle eau pour le traitement de désordres liés à la sénescence cellulaire
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
CN111494366A (zh) * 2019-01-31 2020-08-07 洛阳尚德药缘科技有限公司 二甲基氨基含笑内酯在制备抗衰老药物上的应用
CN110161226A (zh) * 2019-02-27 2019-08-23 杭州晟康细胞生物科技有限公司 一种检测衰老细胞用的抗体、试剂盒及检测方法
EP3705109A1 (fr) 2019-03-05 2020-09-09 Greenaltech, S.L. Caroténoïdes dans le traitement de maladies liées à la sénescence
JP7522458B2 (ja) 2019-03-20 2024-07-25 学校法人順天堂 二重膜構造細胞内小器官ｄｎａ標的薬
EP3947368A4 (fr) 2019-04-04 2023-01-04 Dana-Farber Cancer Institute, Inc. Agents de dégradation de cdk2/5 et utilisations associées
EP3980000A4 (fr) * 2019-06-10 2023-06-21 Buck Institute for Research on Aging Procédés et compositions pour modifier un phénotype sécrétoire associé à la sénescence
WO2020257173A1 (fr) * 2019-06-17 2020-12-24 Unity Biotechnology, Inc. Méthode de traitement de l'articulation ostéoarthritique
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
CN110934873B (zh) * 2019-08-22 2022-10-28 中国科学院上海营养与健康研究所 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
AU2020378279A1 (en) 2019-11-05 2022-05-26 AbbVie Deutschland GmbH & Co. KG Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
WO2021113152A1 (fr) * 2019-12-02 2021-06-10 Viome, Inc. Détection et élimination de cellules aberrantes
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
CA3181134A1 (fr) * 2020-06-02 2021-12-09 Christopher D. WILEY Acide dihomo-gamma-linolenique (dgla) comme nouvel agent senolytique
WO2021257820A1 (fr) * 2020-06-17 2021-12-23 Mayo Foundation For Medical Education And Research Évaluation et traitement d'un vieillissement biologique
CN111973578A (zh) * 2020-08-03 2020-11-24 天津医科大学 C188-9、Venetoclax、Bumetanide在纤维化疾病药物中的应用
KR20220056730A (ko) * 2020-10-28 2022-05-06 의료법인 성광의료재단 Abt263을 유효성분으로 포함하는 디스크 질환 예방 및 치료용 조성물
CN112294962B (zh) * 2020-11-13 2023-06-06 上海长海医院 Bcl-2及bcl-xl抑制剂在瘢痕治疗中的应用
CN112891358B (zh) * 2020-11-19 2023-05-12 苏州正永生物医药有限公司 Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物
JPWO2022138700A1 (fr) * 2020-12-23 2022-06-30
KR102625248B1 (ko) * 2021-05-04 2024-01-16 주식회사 퓨전바이오텍 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물
CN113341126A (zh) * 2021-05-07 2021-09-03 中国科学院动物研究所 一种评价或辅助评价海马组织衰老的标志物
EP4366720A1 (fr) * 2021-07-09 2024-05-15 Georgia State University Research Foundation, Inc. Utilisation de bêta-hydroxybutyrates pour le traitement ou la prévention d'anévrismes et de dissections
CN113509555B (zh) * 2021-07-19 2022-05-03 中国药科大学 Akt2抑制剂在制备非酒精性脂肪肝病治疗药物中的应用
WO2023023654A1 (fr) 2021-08-20 2023-02-23 Siwa Corporation Méthodes et compositions pour traiter des maladies fibrotiques
CN118103006A (zh) * 2021-08-20 2024-05-28 脑部保护私人有限公司 用于治疗病症的包括可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
CN113694071A (zh) * 2021-08-31 2021-11-26 上海交通大学医学院附属瑞金医院 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
CA3232213A1 (fr) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Conjugues medicamenteux de derives de sucre et leurs utilisations en tant qu'agents senolytiques
JP2024534989A (ja) 2021-09-13 2024-09-26 ルベド ライフ サイエンシズ， インク． 新規な糖誘導体、及び新規な老化細胞除去剤を製造するためのその使用
WO2023064326A1 (fr) * 2021-10-12 2023-04-20 University Of Florida Research Foundation, Incorporated Méthodes de traitement de maladies associées à l'accumulation de cellules sénescentes
KR20230080336A (ko) * 2021-11-29 2023-06-07 에스케이케미칼 주식회사 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도
WO2023146979A1 (fr) * 2022-01-27 2023-08-03 The Board Of Trustees Of The Leland Stanford Junior University Plateforme de cytométrie de masse à cellule unique pour cartographier les effets d'agents candidats sur le cartilage
WO2023191513A1 (fr) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 Dérivé d'imidazoline conjugué à un sucre et son utilisation
WO2023235511A1 (fr) * 2022-06-01 2023-12-07 Sens Research Foundation Élimination ciblée de cellules sénescentes par des lymphocytes t gamma-delta
US20240000743A1 (en) * 2022-07-01 2024-01-04 Jjr&D, Llc Method of Preventing and Treating Chemotherapy-Induced Alopecia
WO2024039646A1 (fr) * 2022-08-15 2024-02-22 Mayo Foundation For Medical Education And Research Procédés et matériaux pour utiliser et évaluer des traitements anti-sénescence chez des mammifères
CN118063438A (zh) * 2022-11-14 2024-05-24 北京华益健康药物研究中心 Mdm2/mdmx双靶点抑制剂化合物、前药、药物组合物及其制备方法和应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021342A (en) 1910-04-20 1912-03-26 James D Swindell Furnace.
US1025861A (en) 1911-12-12 1912-05-07 John Martin Case Train-order holder.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
DK0654085T3 (da) 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
AU4769893A (en) 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5700638A (en) 1993-08-26 1997-12-23 Washington University Cell death regulator
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
CA2267139A1 (fr) 1996-10-08 1998-04-16 Ton Logtenberg Procedes et systemes permettant de selectionner des peptides et des proteines qui possedent une affinite specifique envers une cible
WO1999001114A1 (fr) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US20020197602A1 (en) 1998-04-15 2002-12-26 Glenna C. Burmer Nucleic acid sequences and proteins associated with aging
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
US20020068704A1 (en) 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
GB9910119D0 (en) 1999-04-30 1999-06-30 Novartis Ag Organic compounds
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US6656461B1 (en) 2000-02-29 2003-12-02 The Trustees Of Columbia University In The City Of New York Therapeutic treatment of chronic obstructive pulmonary disease
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
CA2454976C (fr) 2001-07-26 2011-05-10 Santen Pharmaceutical Co., Ltd. Agent therapeutique contre le glaucome contenant en tant qu'ingre dient actif un compose presentant un effet inhibiteur de la kinase pi3
WO2003028443A1 (fr) 2001-09-28 2003-04-10 The Walter And Eliza Hall Institute Of Medical Research Procedes de criblage d'agents modulant des troubles degeneratifs associes aux genes bcl-2-et bim
US20030086916A1 (en) 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
MXPA04005906A (es) 2001-12-18 2004-09-13 Hoffmann La Roche Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
US7482134B2 (en) 2002-06-05 2009-01-27 Seoul National University Industry Foundation Signals and molecular species involved in senescence
FI117094B (fi) * 2003-01-15 2006-06-15 Fractivator Oy Menetelmä orgaanisen jätteen hajottamiseksi
EP2336298B1 (fr) * 2003-06-27 2016-02-17 DePuy Synthes Products, Inc. Cellules isolées de placenta post-partum, méthodes pour leur préparation et leur utilisation.
WO2005020996A1 (fr) * 2003-08-29 2005-03-10 Kowa Co., Ltd. Procede pour stabiliser une plaque riche en lipides et procede pour prevenir la rupture de ladite plaque
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (fr) 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
GB0411166D0 (en) 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
PT1768966E (pt) 2004-06-17 2012-05-23 Infinity Discovery Inc Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
GB0418388D0 (en) 2004-08-18 2004-09-22 Univ Newcastle Cell therapy
US20060122150A1 (en) 2004-09-30 2006-06-08 Argentieri Dennis C Pharmaceutical composition and method for treating a joint-capsule arthropathy
PL2757099T3 (pl) 2005-05-12 2018-02-28 Abbvie Bahamas Limited Promotory apoptozy
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2007014783A (es) 2005-05-24 2008-02-19 Abbott Lab Activadores de apoptosis.
EP2130822A1 (fr) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG Dérivés de 2,4,5-triphényl imidazoline en tant qu'inhibiteurs de l'interaction entre les proteines p53 et mdm2, utilisés en tant qu'agents anticancereux
WO2007130134A2 (fr) 2005-12-02 2007-11-15 (Osi) Eyetech, Inc. Microparticules à libération contrôlée
EP1979338A1 (fr) 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Imidazolines cis-4,5-biaryl-2-hétérocycliques utilisées comme inhibiteurs de mdm2
US8614192B2 (en) * 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
US8470785B2 (en) * 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
EP2054121A4 (fr) 2006-08-11 2009-12-23 Inst Medical W & E Hall Procédés de modulation de l'apoptose dans les plaquettes
ZA200901224B (en) * 2006-08-30 2010-05-26 Univ Michigan New small molecule inhibitors of MDM2 the uses thereof
CA2662320C (fr) 2006-09-05 2014-07-22 Abbott Laboratories Inhibiteurs de bcl pour le traitement de l'exces de plaquettes
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
CN101641338A (zh) * 2006-09-11 2010-02-03 柯瑞斯公司 作为抗增殖制剂的多功能小分子
JP5366817B2 (ja) 2006-11-15 2013-12-11 ジェネンテック， インコーポレイテッド アリールスルホンアミド化合物
US20100087436A1 (en) 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20080125487A1 (en) * 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008106507A2 (fr) * 2007-02-27 2008-09-04 University Of South Florida Peptide inhibiteur de mdm2/mdmx
CN101680886A (zh) 2007-03-20 2010-03-24 沃尔特及伊莱萨霍尔医学研究院 筛选方法
AU2008234954B9 (en) * 2007-03-29 2012-02-02 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
US20110028437A1 (en) 2007-07-31 2011-02-03 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
WO2009042798A1 (fr) * 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Procédés de traitement d'une fibrose par modulation de la sénescence cellulaire
EP2193127A4 (fr) 2007-09-27 2011-09-14 Inst Medical W & E Hall Composés de benzothiazole
EP2205088B1 (fr) 2007-10-19 2018-02-21 Burnham Institute for Medical Research Inhibiteurs à base de naphtalène de protéines anti-apoptotiques
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2009105234A2 (fr) 2008-02-19 2009-08-27 Combinatorx, Incorporated Procédés et compositions pour le traitement de troubles associés à des défauts du gène ou de la protéine du régulateur de la conductance transmembranaire d'une fibrose kystique
EP2282755A4 (fr) 2008-03-20 2015-06-17 Morphotek Inc Inhibition de l'angiogenèse
WO2009120186A1 (fr) 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Procédés et compositions pour traiter l'athérosclérose et des états associés
US7782903B2 (en) 2008-05-14 2010-08-24 Newport Media, Inc. Hardware accelerated protocol stack
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102099013A (zh) 2008-07-14 2011-06-15 奥德纳米有限公司 用于治疗耳部病症的控制释放凋亡调节组合物和方法
WO2010040232A1 (fr) 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Utilisation de scyllo-inositols pour le traitement de troubles liés à la dégénérescence maculaire
CN101507729B (zh) 2008-10-23 2010-12-22 昆明诺唯金参生物工程有限责任公司 人参皂苷Compound K在制备防治动脉粥样硬化的药物中的应用
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2358748B1 (fr) * 2008-12-09 2016-07-06 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour la modulation spécifique de mcl-1
AU2009335818A1 (en) 2008-12-19 2011-07-21 Abbvie Inc. Compounds and methods of use
NZ593537A (en) 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use
US20130302283A1 (en) * 2012-05-14 2013-11-14 Advanced Technologies And Regenerative Medicine, Llc hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
MX2011007681A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
EP2416771A4 (fr) * 2009-04-09 2012-10-31 Oncothyreon Inc Méthodes et compositions d'inhibiteurs de pi3 kinase utilisées dans le traitement des fibroses
EA023244B1 (ru) 2009-04-10 2016-05-31 Хаян Ки Способ предотвращения старения клеток
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010148447A1 (fr) 2009-06-23 2010-12-29 Centenary Institute Of Cancer Medicine And Cell Biology Nouveau régulateur de la sénescence cellulaire
AU2010295717B2 (en) * 2009-09-20 2014-09-11 Abbvie Inc. ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
RU2576512C2 (ru) 2009-11-04 2016-03-10 Хэлс Ресеч Инк. Способ и композиции для подавления старения
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
EP2521594A2 (fr) 2010-01-07 2012-11-14 Akron Molecules GmbH Petites molécules pour traiter l'obésité
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
US10159669B2 (en) 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
SG184094A1 (en) 2010-03-25 2012-10-30 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8675704B2 (en) 2010-04-29 2014-03-18 Sri International Single ridge N-P-N diode laser
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
EP2598168A4 (fr) * 2010-07-28 2014-03-26 Merck Sharp & Dohme Polythérapie pour le traitement du cancer comprenant un inhibiteur d'igf-1r et un inhibiteur d'akt
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
US9102668B2 (en) 2010-09-08 2015-08-11 Glaxo Group Limited Polymorphs and salts
US20130225603A1 (en) 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2966040A1 (fr) 2010-10-19 2012-04-20 Brigitte Gourlaouen Composition amincissante et/ou de prevention des processus inflammatoires
BR112013009093B1 (pt) 2010-10-29 2022-04-19 Abbvie Inc Processo para a preparação de uma dispersão sólida contendo um agente indutor de apoptose
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US8741905B2 (en) 2010-11-05 2014-06-03 The Broad Institute, Inc. Compounds and methods for treating autoimmune diseases
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
AU2011325910B2 (en) 2010-11-12 2016-03-24 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
KR20190109590A (ko) 2010-11-23 2019-09-25 애브비 아일랜드 언리미티드 컴퍼니 선택적인 ｂｃｌ­２ 억제제를 사용하는 치료 방법
CN103562202B (zh) 2011-01-25 2016-09-14 密执安大学评议会 Bcl-2/bcl-xl抑制剂和使用它们的治疗方法
CA2825825A1 (fr) 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibiteurs de kinase mtor en tant qu'agents antiviraux
EP2675448B1 (fr) 2011-01-31 2017-01-11 Tokyo University of Science Foundation Procédé de traitement d'une lésion ischémique/de reperfusion
EP2683733B1 (fr) 2011-03-07 2017-08-30 Fondazione Telethon Variants de tfeb et leurs utilisations médicales
KR101426689B1 (ko) * 2011-04-19 2014-08-08 가톨릭대학교 산학협력단 Ｎｕｔｌｉｎ­３ａ 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
TWI497333B (zh) 2011-06-14 2015-08-21 Giant Mfg Co Ltd 自行車適配產生方法、自行車適配系統與電腦程式產品
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9140213B2 (en) * 2011-12-06 2015-09-22 United Technologies Corporation Leaf spring damper for a turbine engine fuel delivery system
CN104125836A (zh) 2011-12-13 2014-10-29 巴克老龄化研究所 改善医疗治疗的方法
US8747112B2 (en) 2011-12-30 2014-06-10 Nobel Biocare Services Ag Abutment position locator
RU2014128387A (ru) 2012-02-06 2016-03-27 ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед Ингибиторы рi3к для лечения фиброзных заболеваний
WO2013155077A1 (fr) 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Marqueurs de réponse pour thérapies par inhibiteur de src
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
KR101725571B1 (ko) * 2012-06-13 2017-04-11 가톨릭대학교 산학협력단 Ｍｄｍ２ 억제제를 유효성분으로 포함하는 노화 억제용 조성물
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
ES2677480T3 (es) 2012-08-13 2018-08-02 Abbvie Inc. Agentes que inducen apoptosis
US9104666B2 (en) 2012-09-04 2015-08-11 Oracle International Corporation Controlling access to a large number of electronic resources
KR101698283B1 (ko) 2012-10-10 2017-01-19 에프. 호프만-라 로슈 아게 티에노피리미딘 화합물의 제조 방법
EP2945940B1 (fr) 2013-01-16 2020-07-15 The Regents of The University of Michigan Inhibiteurs de bcl-2/bcl-xl et leur utilisation dans le traitement du cancer
EP4309657A3 (fr) 2013-02-01 2024-02-28 Celator Pharmaceuticals, Inc. Chargement a distance de medicaments faiblement solubles dans l'eau dans des liposomes
WO2014137946A1 (fr) 2013-03-04 2014-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Procédés d'inhibition de l'activation de igf-1r ou de la signalisation en aval de celui-ci pour réduire la sénescence cellulaire induite par rayonnement
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2970383T3 (da) 2013-03-15 2021-07-05 Univ Texas Fremgangsmåde til behandling af fibrose
US20140272947A1 (en) 2013-03-15 2014-09-18 Fox Chase Cancer Center Methods and compositions for screening modulators of oncogene-induced senescence
RU2015149680A (ru) 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
WO2014186877A1 (fr) 2013-05-24 2014-11-27 Uger Marni Diane Anticorps dirigés contre le récepteur fas à usage diagnostique et thérapeutique
AR096673A1 (es) 2013-06-19 2016-01-27 Buck Inst For Res On Aging Métodos para aumentar la eficacia de terapias médicas
US20160022720A1 (en) 2013-08-02 2016-01-28 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
WO2015051252A1 (fr) 2013-10-03 2015-04-09 Duke University Compositions et méthodes destinées à traiter les cancers ayant une activité jak2
US9909125B2 (en) 2013-11-01 2018-03-06 Everon Biosciences, Inc. Molecular targets for selective eradication of senescent cells
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
US20190000846A1 (en) 2014-01-28 2019-01-03 Mayo Foundation For Medical Education And Research Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
WO2015116740A1 (fr) 2014-01-28 2015-08-06 Buck Institute For Research On Aging Procédés et compositions permettant de tuer les cellules sénescentes et de traiter les maladies et les troubles associés à la sénescence
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
GB201409519D0 (en) 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
EP3253387A4 (fr) 2015-02-06 2018-12-19 Unity Biotechnology, Inc. Composés et utilisations dans le traitement d' états associés à la sénescence
US20180000816A1 (en) 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye

Also Published As

Publication number Publication date
CA3100140A1 (fr) 2015-08-06
US10478432B2 (en) 2019-11-19
EP3099380B1 (fr) 2021-08-11
SG11201606239UA (en) 2016-08-30
EP3099380A1 (fr) 2016-12-07
US20170224680A2 (en) 2017-08-10
US9849128B2 (en) 2017-12-26
IL286427A (en) 2021-10-31
US9855266B2 (en) 2018-01-02
US10328073B2 (en) 2019-06-25
KR102496146B1 (ko) 2023-02-06
US20190022090A1 (en) 2019-01-24
JP2023126918A (ja) 2023-09-12
US20180235957A1 (en) 2018-08-23
US20170209435A1 (en) 2017-07-27
US20190343832A1 (en) 2019-11-14
US20180117038A1 (en) 2018-05-03
US10478433B2 (en) 2019-11-19
HK1231392A1 (zh) 2017-12-22
US20200030323A1 (en) 2020-01-30
US20210169876A1 (en) 2021-06-10
US10413542B2 (en) 2019-09-17
AU2015211021A1 (en) 2016-09-01
CN112274641A (zh) 2021-01-29
CA3100140C (fr) 2023-10-24
AU2015211021B2 (en) 2020-07-02
CN110623956A (zh) 2019-12-31
IL246954B (en) 2022-02-01
BR112016017564A8 (pt) 2018-04-17
CA2939121C (fr) 2020-11-24
US20170348307A1 (en) 2017-12-07
EP3669881B1 (fr) 2022-03-30
US20180303828A1 (en) 2018-10-25
US9993472B2 (en) 2018-06-12
CN106163557B (zh) 2020-07-14
US20180250296A1 (en) 2018-09-06
US20170198253A1 (en) 2017-07-13
JP2019142933A (ja) 2019-08-29
KR20160117519A (ko) 2016-10-10
US20180256568A1 (en) 2018-09-13
US9980962B2 (en) 2018-05-29
JP6688224B2 (ja) 2020-04-28
JP2020105213A (ja) 2020-07-09
RU2016134429A3 (fr) 2018-10-01
WO2015116740A1 (fr) 2015-08-06
IL286427B2 (en) 2024-08-01
US10213426B2 (en) 2019-02-26
RU2716256C2 (ru) 2020-03-11
MX2016009753A (es) 2017-07-07
AU2020244600A1 (en) 2020-11-05
US10258618B2 (en) 2019-04-16
IL286427B1 (en) 2024-04-01
US11963957B2 (en) 2024-04-23
EP3669881A1 (fr) 2020-06-24
US20180235956A1 (en) 2018-08-23
CN106163557A (zh) 2016-11-23
MX2021012547A (es) 2021-11-12
US11351167B2 (en) 2022-06-07
US20170196858A1 (en) 2017-07-13
EP3099380A4 (fr) 2017-09-27
BR112016017564A2 (pt) 2017-10-03
US20160339019A1 (en) 2016-11-24
JP2017532285A (ja) 2017-11-02
RU2016134429A (ru) 2018-03-01
US11980616B2 (en) 2024-05-14
JP2021138712A (ja) 2021-09-16
US20210030752A1 (en) 2021-02-04
US10517866B2 (en) 2019-12-31
US20210169875A1 (en) 2021-06-10
US20170196857A1 (en) 2017-07-13
IL311537A (en) 2024-05-01
US10130628B2 (en) 2018-11-20
CA2939121A1 (fr) 2015-08-06
NZ723035A (en) 2022-07-01
AU2022256167A1 (en) 2023-01-19
US20170326136A1 (en) 2017-11-16
IL246954A0 (en) 2016-09-29
US10010546B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
MX2021009673A (es) Moduladores de ror-gamma.
ZA201702799B (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
EP3359662A4 (fr) Compositions et méthodes pour traiter la maladie de huntington et les troubles apparentés
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015148863A3 (fr) Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
WO2014179564A8 (fr) Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
WO2017132432A8 (fr) Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma
WO2016066744A3 (fr) Composés agonistes de gip et procédés associés
WO2016172496A8 (fr) Inhibiteurs de lsd1 et leurs utilisations
WO2015143447A3 (fr) Méthodes de traitement de troubles neurologiques
WO2016149501A3 (fr) Agents thérapeutiques modifiés et compositions associées
EP3122872A4 (fr) Compositions et méthodes destinées à traiter le diabète de type 1 et type 2 et autres troubles associés
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2016077639A3 (fr) Thérapies nanovésiculaires
EP3182979A4 (fr) Nouvelles compositions et méthodes utiles pour traiter ou prévenir des maladies ou des troubles hépatiques et favoriser la perte de poids
WO2016089886A3 (fr) Méthodes de traitement de la kératoconjonctivite sèche par administration d'un antagoniste de l'il-6r
MX2017002610A (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EA201791021A1 (ru) 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016010447A (es) Composiciones y metodos para tratar diabetes y enfermedades hepáticas.
WO2017008033A8 (fr) Dérivés de carboxamido pyrrolidine et leurs procédés de préparation et d'utilisation